tradmap

RDNT Radnet, Inc.

$73.11 -0.54%

Data as of close

Healthcare · Services-Medical Laboratories

Radnet, Inc. (RDNT) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $5.8 billion. Shares last traded at $73.11, 14.7% below their 52-week high. Over the past year the stock is down 3.9%. Net profit margin is -0.9%, above the peer median of -5.4%. Revenue grew 11.5% year over year.

Market Cap
$5.8B
Shares Out
78.7M
EPS (TTM)
-$0.26
P/E (TTM)*
—
P/S Ratio
2.54
P/B Ratio
5.25
Dividend / Share
—
Dividend Yield
—
52-Week High
$85.74
52-Week Low
$50.96
Volume (venue)
78,236
Avg Vol (3m, venue)
38,865.048

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+4.35%
1M
+4.62%
3M
+5.57%
6M
+25.55%
YTD
+2.59%
1Y
-3.89%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
56.37
SMA (50)
$72.49
SMA (200)
$65.14
Price vs SMA50
+0.84%
Price vs SMA200
+12.23%
ATR (14)
$2.48

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$2.3B
Net Income
-$21M
Gross Margin
—
Operating Margin
3.1%
Net Margin
-0.9%
Return on Equity
-1.9%
Return on Assets
-0.5%
Current Ratio
1.48
Debt / Equity
1.22
Revenue Growth (YoY)
+11.5%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.10 2026-08-10
Q1 2026 -$0.43 2026-05-11
Q4 2025 (derived) $0.00 2026-03-02
FY 2025 -$0.25 2026-03-02
Q3 2025 $0.07 2025-11-10
Q2 2025 $0.19 2025-08-11

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Services-Medical Laboratories peers

RDNT vs 14 industry peers (Services-Medical Laboratories), by market cap. Data as of close

P/S vs peers
2.54 / 5.00 med
-49% discount
Net margin vs peers
-0.9% / -5.4% med
above median
1–14 of 14
NTRANatera, Inc.$54.6B—20.18-7.1%-8.49%
LHLabcorp$28.9B28.771.986.9%-1.65%
DGXQuest Diagnostics$27.6B24.442.339.5%-0.44%
GHGuardant Health, Inc.$22.9B—19.38-38.3%-4.45%
CAICaris Life Sciences, Inc.$9.1B86.269.1610.6%-6.50%
GRALGrail, Inc.$6.0B———-6.79%
RDNTRadnet, Inc.$5.8B—2.54-0.9%-0.54%
BLLNBilliontoone, Inc.$5.2B138.0913.109.5%-2.52%
CDNACaredx, Inc.$4.5B35.089.0725.9%-1.68%
VCYTVeracyte, Inc.$3.9B34.457.0220.4%-1.87%
CELCCelcuity Inc.$3.3B———-2.90%
FTREFortrea Holdings Inc.$1.9B—0.72-2.6%-5.99%
PSNLPersonalis, Inc.$1.7B———-0.44%
LMRILumexa Imaging Holdings, Inc.$1.1B———-2.32%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.